Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer
  2. Aide
  2. Aide
CAC 40
7 696,31
-0,03%
Indices
Chiffres-clés
+ fortes hausses et baisses SBF 120

Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
information fournie par Boursorama CP 09/11/2020 à 17:45

­ - Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5%
­ - Presence of liver metastases had a notable impact on outcomes: in patients without liver metastases, an ORR of 34.8% and a median progression-free survival (PFS) of 5.6 months were achieved
­ - Treatment associated with changes in the tumor microenvironment characterized by a significant and sustainable immune response and activity against the tumor

Conference call to take place on November 12, at 6:00 p.m. CET (in English).

.../...

Valeurs associées

TRANSGENE
1,1000 EUR Euronext Paris -0,45%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.
Chargement...

Pages les plus populaires

L'offre BoursoBank